Evaluation of Pcv-aCO2 in the Fluid Treatment of Abdominal Tumor Patients After Surgery

Abdominal Infection Clinical Trial

Official title: Clinical Study of Central Venous-to-Arterial Carbon Dioxide Difference(Pcv-aCO2) in the Evaluation of Fluid Therapy for Postoperative Patients With Abdominal Cancer

Status Recruiting

Clinical Trial Summary

This research will confirm that Pcv-aCO2 is suitable for the guidance of early fluid therapy and the evaluation of the prognosis of patients with abnormal hemodynamics after abdominal tumor surgery, and is expected to be a new monitoring index to improve the therapeutic effect of these patients.

Clinical Trial Description

1. Confirmed that Pcv-aCO2 is suitable for the guidance of early fluid therapy and the evaluation of the prognosis of patients with abnormal hemodynamics after abdominal tumor surgery, and is expected to be a new monitoring index to improve the therapeutic efficacy of this kind of patients.

2. Pcv-aCO2 effectively reflected the improvement of tissue and organ microcirculation disorder through the individual goal target treatment to guide the fluid resuscitation in the hemodynamic instability patients.

3. Research of the correlation between Pcv-aCO2 and the organ function in patients with abnormal hemodynamics after operation. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Abdominal Infection
• Abdominal Neoplasms
• Abdominal Tumor
• Intraabdominal Infections

• NCT number: NCT02977429
• Study type: Interventional
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Yang Yang, physician
• Phone: 022-23340123
• Email: yyicu3021@126.com
• Status: Recruiting
• Phase: N/A
• Start date: October 2016
• Completion date: September 2018